SG11202002235XA - 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors - Google Patents

1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors

Info

Publication number: SG11202002235XA
Authority: SG; Singapore
Prior art keywords: imino; benzyl; phenyl; protease inhibitors; hiv protease
Prior art date: 2017-10-13

Buenrostro Ana Zurisadai Gonzalez

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-10-12Application filed by Gilead Sciences IncfiledCriticalGilead Sciences Inc

2020-04-29Publication of SG11202002235XApublicationCriticalpatent/SG11202002235XA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D247/00—Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups C07D229/00 - C07D245/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Peptides Or Proteins (AREA)

SG11202002235XA2017-10-132018-10-121-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitorsSG11202002235XA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762572243P	2017-10-13	2017-10-13
PCT/US2018/055554WO2019075291A1 (en)	2017-10-13	2018-10-12	1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors

Publications (1)

Publication Number	Publication Date
SG11202002235XAtrue SG11202002235XA (en)	2020-04-29

Family

ID=64051787

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202002235XASG11202002235XA (en)	2017-10-13	2018-10-12	1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors

Country Status (23)

Country	Link
US (2)	US10774053B2 (en)
EP (1)	EP3694846B1 (en)
JP (2)	JP7136892B2 (en)
KR (1)	KR102515284B1 (en)
CN (1)	CN111212832B (en)
AR (1)	AR113765A1 (en)
AU (1)	AU2018347541C1 (en)
BR (1)	BR102018071016A2 (en)
CA (1)	CA3076761C (en)
CL (1)	CL2020000886A1 (en)
CO (1)	CO2020004301A2 (en)
CR (1)	CR20200149A (en)
EA (1)	EA202090530A1 (en)
ES (1)	ES2979368T3 (en)
IL (1)	IL273842A (en)
JO (1)	JOP20180092A1 (en)
MX (1)	MX2020003430A (en)
PE (1)	PE20201497A1 (en)
PH (1)	PH12020550256A1 (en)
PL (1)	PL3694846T3 (en)
SG (1)	SG11202002235XA (en)
TW (2)	TW202045490A (en)
WO (1)	WO2019075291A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY190386A (en)	2017-04-11	2022-04-20	Mitsui Chemicals Agro Inc	Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients
CA3128961A1 (en)	2019-03-22	2020-10-01	Hang CHU	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
WO2020214647A1 (en)*	2019-04-17	2020-10-22	Gilead Sciences, Inc.	Solid forms of an hiv protease inhibitor
TW202104210A (en)*	2019-04-17	2021-02-01	美商基利科學股份有限公司	Hiv protease inhibitors
WO2021188959A1 (en)	2020-03-20	2021-09-23	Gilead Sciences, Inc.	Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022022530A2 (en)	2020-05-05	2023-02-23	Nuvalent Inc	COMPOUND, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OF CANCER, METHOD OF SELECTIVE INHIBITION, METHOD OF REDUCING A LEVEL OF ROS1 OR ALK
CN115916754A (en)	2020-05-05	2023-04-04	纽威伦特公司	Heteroaromatic macrocyclic ether chemotherapeutic agents
TW202406932A (en)	2020-10-22	2024-02-16	美商基利科學股份有限公司	Interleukin-2-fc fusion proteins and methods of use
CA3195799A1 (en)	2020-11-11	2022-05-19	Stephen R. Martin	Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
KR20240087788A (en)	2021-10-01	2024-06-19	뉴베일런트, 아이엔씨.	Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
WO2023074936A1 (en)*	2021-10-27	2023-05-04	주식회사 오토텍바이오	Bifunctional compound using ubr box domain-binding ligand
TW202342447A (en)	2021-12-03	2023-11-01	美商基利科學股份有限公司	Therapeutic compounds for hiv virus infection
EP4440702B1 (en)	2021-12-03	2025-05-21	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
EP4440700A1 (en)	2021-12-03	2024-10-09	Gilead Sciences, Inc.	Therapeutic compounds for hiv virus infection
TWI856796B (en)	2022-04-06	2024-09-21	美商基利科學股份有限公司	Bridged tricyclic carbamoylpyridone compounds and uses thereof
CN115260167B (en)*	2022-08-01	2025-01-21	陕西盘龙药业集团股份有限公司	A 3-tetrazolylmethyl-1,3,5-triazine-2,4-dione compound and its preparation method and application
WO2024044477A1 (en)	2022-08-26	2024-02-29	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en)	2022-10-04	2024-07-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
CN116270698A (en)*	2023-03-01	2023-06-23	上海复星医药产业发展有限公司	Compound solid preparation and preparation method and application thereof
CN116270699A (en)*	2023-03-07	2023-06-23	上海复星医药产业发展有限公司	A kind of tripartite preparation and its preparation method and application
WO2024220624A1 (en)	2023-04-19	2024-10-24	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
WO2024249573A1 (en)	2023-05-31	2024-12-05	Gilead Sciences, Inc.	Solid forms of compounds useful in the treatment of hiv
WO2025029247A1 (en)	2023-07-28	2025-02-06	Gilead Sciences, Inc.	Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Dosing regimen of hiv capsid inhibitor
US20250127801A1 (en)	2023-10-11	2025-04-24	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250120989A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025137245A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
WO2025184447A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184452A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
IL102183A (en)	1991-06-27	1999-11-30	Takeda Chemical Industries Ltd	Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
GB0016787D0 (en)*	2000-07-07	2000-08-30	Pfizer Ltd	Compounds useful in therapy
DK1762567T3 (en)*	2001-04-10	2012-06-25	Pfizer	Pyrazole derivatives for the treatment of HIV
ATE490788T1 (en)	2003-04-25	2010-12-15	Gilead Sciences Inc	ANTIVIRAL PHOSPHONATE ANALOGUE
US7763609B2 (en)*	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
CA2548388A1 (en)	2003-12-15	2005-06-30	Schering Corporation	Heterocyclic aspartyl protease inhibitors
DOP2005000123A (en)	2004-07-02	2011-07-15	Merck Sharp & Dohme	CETP INHIBITORS
PT1778251E (en)	2004-07-27	2011-06-29	Gilead Sciences Inc	Nucleoside phosphonate conjugates as anti hiv agents
CA2629815C (en)	2005-11-14	2014-08-12	University Of Southern California	Integrin-binding small molecules
US8486983B2 (en)	2005-12-05	2013-07-16	Merck Sharp & Dohme Corp.	Self-emulsifying formulations of CETP inhibitors
CN101365689A (en)	2005-12-30	2009-02-11	默克公司	1,3-oxazolidin-2-one derivatives useful as cetp inhibitors
EP1971595B1 (en)	2005-12-30	2013-10-16	Merck Sharp & Dohme Corp.	Cetp inhibitors
WO2007081571A2 (en)	2005-12-30	2007-07-19	Merck & Co., Inc.	Cetp inhibitors
BRPI0707584A2 (en)	2006-02-09	2011-05-10	Merck & Co Inc	pharmaceutical composition, use of the pharmaceutical composition, and pharmaceutical formulation
SG185995A1 (en)	2007-11-16	2012-12-28	Gilead Sciences Inc	Inhibitors of human immunodeficiency virus replication
US20110065916A1 (en)	2007-11-26	2011-03-17	Mark Spyvee	Method of making imidazoazepinone compounds
AP2011005745A0 (en)	2008-12-09	2011-06-30	Gilead Sciences Inc	Modulators of toll-like receptors.
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
WO2011133719A2 (en)	2010-04-23	2011-10-27	Kineta, Inc.	Anti-viral compounds
WO2011139637A1 (en)	2010-05-03	2011-11-10	Philadelphia Health & Education Corporation	Small-molecule modulators of hiv-1 capsid stability and methods thereof
AP2013006706A0 (en)	2010-07-02	2013-02-28	Gilead Sciences Inc	Napht-2-ylacetic acid derivatives to treat AIDS
PH12013500015A1 (en)	2010-07-02	2013-02-18	Gilead Sciences Inc	2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
EP3181555B1 (en)	2011-04-21	2018-11-28	Gilead Sciences, Inc.	Benzothiazole compounds and their pharmaceutical use
US9540343B2 (en)	2011-07-06	2017-01-10	Gilead Sciences, Inc.	Compounds for the treatment of HIV
CN102863512B (en)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	Antiviral compound
US9399645B2 (en)	2011-12-20	2016-07-26	Boehringer Ingelheim International Gmbh	Inhibitors of HIV replication
RU2014115227A (en)	2012-04-20	2015-10-27	Джилид Сайэнс, Инк.	DERIVATIVES OF BENZOTIAZOL-6-IL ACETIC ACID AND THEIR APPLICATION FOR TREATMENT OF HIV INFECTION
US9169214B2 (en)	2012-12-21	2015-10-27	The Board Of Trustees Of The Leland Stanford Junior University	Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
BR122015029881B1 (en)	2012-12-21	2022-04-26	Gilead Sciences, Inc	Polycyclic carbamoylpyridone compounds, pharmaceutical composition comprising them and their pharmaceutical use
AU2013366981A1 (en)	2012-12-27	2015-06-18	Japan Tobacco Inc.	Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor
US9840471B2 (en)	2013-02-19	2017-12-12	Senomyx, Inc.	Compounds useful as modulators of TRPM8
EP2968995B1 (en)	2013-03-15	2018-05-09	Elan Pharmaceuticals LLC	Inhibitors of lrrk2 kinase activity
JP6480909B2 (en)	2013-03-15	2019-03-13	ユニバーシティーオブサウザンカリフォルニア	Methods, compounds and compositions for the treatment of angiotensin related diseases
US20190046507A1 (en)	2016-02-18	2019-02-14	Merck Sharp & Dohme Corp.	Compounds for the treatment of malaria
US10696639B2 (en)	2016-12-06	2020-06-30	Merck Sharp & Dohme Corp.	Heterocyclic compounds as HIV protease inhibitors
US20200069691A1 (en)*	2016-12-22	2020-03-05	Merck Sharp & Dohme Corp.	Heterocyclic compounds as hiv protease inhibitors
US20200261421A1 (en)*	2016-12-22	2020-08-20	Merck Sharp & Dohme Corp.	Heterocyclic compounds as hiv protease inhibitors

2017
- 2017-10-13JOJOP/2018/0092Apatent/JOP20180092A1/enunknown
2018
- 2018-10-11BRBR102018071016-8Apatent/BR102018071016A2/ennot_activeApplication Discontinuation
- 2018-10-12USUS16/158,446patent/US10774053B2/enactiveActive
- 2018-10-12TWTW109119188Apatent/TW202045490A/enunknown
- 2018-10-12CACA3076761Apatent/CA3076761C/enactiveActive
- 2018-10-12CRCR20200149Apatent/CR20200149A/enunknown
- 2018-10-12EPEP18796285.7Apatent/EP3694846B1/enactiveActive
- 2018-10-12KRKR1020207013543Apatent/KR102515284B1/enactiveActive
- 2018-10-12TWTW107135975Apatent/TWI697491B/enactive
- 2018-10-12PLPL18796285.7Tpatent/PL3694846T3/enunknown
- 2018-10-12JPJP2020520483Apatent/JP7136892B2/enactiveActive
- 2018-10-12ESES18796285Tpatent/ES2979368T3/enactiveActive
- 2018-10-12SGSG11202002235XApatent/SG11202002235XA/enunknown
- 2018-10-12WOPCT/US2018/055554patent/WO2019075291A1/ennot_activeCeased
- 2018-10-12ARARP180102964Apatent/AR113765A1/enunknown
- 2018-10-12MXMX2020003430Apatent/MX2020003430A/enunknown
- 2018-10-12CNCN201880066480.8Apatent/CN111212832B/enactiveActive
- 2018-10-12AUAU2018347541Apatent/AU2018347541C1/enactiveActive
- 2018-10-12EAEA202090530Apatent/EA202090530A1/enunknown
- 2018-10-12PEPE2020000525Apatent/PE20201497A1/enunknown
2020
- 2020-04-01CLCL2020000886Apatent/CL2020000886A1/enunknown
- 2020-04-06ILIL273842Apatent/IL273842A/enunknown
- 2020-04-08COCONC2020/0004301Apatent/CO2020004301A2/enunknown
- 2020-04-13PHPH12020550256Apatent/PH12020550256A1/enunknown
- 2020-07-09USUS16/925,096patent/US11352329B2/enactiveActive
2021
- 2021-08-03JPJP2021127542Apatent/JP2021178852A/ennot_activeWithdrawn

Also Published As

Publication number	Publication date
EP3694846A1 (en)	2020-08-19
EP3694846B1 (en)	2024-05-08
US11352329B2 (en)	2022-06-07
KR102515284B1 (en)	2023-03-31
TW202045490A (en)	2020-12-16
CA3076761C (en)	2024-03-26
TW201927766A (en)	2019-07-16
US10774053B2 (en)	2020-09-15
KR20200071098A (en)	2020-06-18
PL3694846T3 (en)	2024-08-26
PH12020550256A1 (en)	2021-03-01
AU2018347541A1 (en)	2020-04-16
IL273842A (en)	2020-05-31
EA202090530A1 (en)	2020-10-06
ES2979368T3 (en)	2024-09-25
CR20200149A (en)	2020-05-22
CN111212832B (en)	2023-09-15
AU2018347541C1 (en)	2022-01-13
AR113765A1 (en)	2020-06-10
CL2020000886A1 (en)	2020-10-09
JP7136892B2 (en)	2022-09-13
US20210078959A1 (en)	2021-03-18
JP2021178852A (en)	2021-11-18
WO2019075291A1 (en)	2019-04-18
JOP20180092A1 (en)	2019-04-13
CN111212832A (en)	2020-05-29
MX2020003430A (en)	2020-07-29
PE20201497A1 (en)	2020-12-29
CA3076761A1 (en)	2019-04-18
AU2018347541B2 (en)	2021-06-17
CO2020004301A2 (en)	2020-05-15
JP2020536911A (en)	2020-12-17
BR102018071016A2 (en)	2019-05-07
EP3694846C0 (en)	2024-05-08
US20190210978A1 (en)	2019-07-11
TWI697491B (en)	2020-07-01

Publication	Publication Date	Title
IL273842A (en)	2020-05-31	1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
IL282103A (en)	2021-05-31	Purinones as ubiquitin-specific protease 1 inhibitors
IL268282A (en)	2019-09-26	Hiv inhibitor compounds
ZA201905811B (en)	2020-06-24	Novel inhibitors
IL256265B (en)	2021-08-31	3-tetrazolyl-benzene-1, 2-disulfonamide derivatives as metallo-beta-lactamase inhibitors
EP3194369A4 (en)	2018-02-28	Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
EP3447058A4 (en)	2019-11-27	Novel broad-spectrum -lactamase inhibitor
ZA201701575B (en)	2018-12-19	Pyrrolidinone derivatives as metap-2 inhibitors
IL265138B (en)	2021-08-31	Blood-brain barrier-penetrant dopamine-b-hydroxylase inhibitors
EP3142659A4 (en)	2017-09-27	Hiv-1 protease inhibitors and uses thereof
EP3116862A4 (en)	2017-08-30	Piperazine derivatives as hiv protease inhibitors
SG11201701378WA (en)	2018-01-30	Pyrido-oxazinone derivatives as tnap inhibitors
EP3113780A4 (en)	2018-02-21	Hiv protease inhibitors
EP3192794A4 (en)	2018-06-27	Sustained hiv protease inhibitor
IL253322A0 (en)	2017-09-28	Bace1 inhibitors
EP3104705A4 (en)	2017-06-21	Cathepsin cysteine protease inhibitors
SMT202100381T1 (en)	2021-09-14	Pyrazolylaminobenzimidazole derivatives as jak inhibitors
HK40021803B (en)	2024-02-02	1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
GB201715589D0 (en)	2017-11-08	Protease inhibitors
HK40017687A (en)	2020-09-25	Dopamine-b-hydroxylase inhibitors
GB201616201D0 (en)	2016-11-09	Blood-brain barrier-penetrant dopamine-B-hydroxylase inhibitors
HK1235061A1 (en)	2018-03-02	Pyrazolyl-substituted pyridone compounds as serine protease inhibitors

Movatterモバイル変換

SG11202002235XA - 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=64051787

Family Applications (1)

Country Status (23)

Families Citing this family (30)

Family Cites Families (44)

Also Published As

Similar Documents